Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.2042-3306.1971.tb04448.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review on whole-body photobiomodulation for exercise performance and recovery.
Lasers Med Sci
January 2025
Cornell University, Ithaca, USA.
Purpose: Photobiomodulation (PBM) is a non-invasive therapeutic procedure that consists of irradiating a local area of the skin with red and near-infrared lasers or light emitting diodes (LEDs). Local PBM has been studied as a method to improve exercise performance and recovery. This review aims to evaluate the efficacy of whole-body PBM for exercise performance and recovery, comparing its findings to the established effects of localized PBM.
View Article and Find Full Text PDFBackground: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.
View Article and Find Full Text PDFThe Effect of Dapagliflozin on Heart Function in Animal Models of Cardiac Ischemia, A Systematic Review and Meta-analysis.
Curr Rev Clin Exp Pharmacol
January 2025
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Introduction: In this study, a meta-analysis was conducted to investigate the therapeutic effect of Dapagliflozin (DAPA) on animals suffering from myocardial ischemia reperfusion compared to the group that did not receive treatment.
Methods: According to the inclusion and exclusion criteria two researchers performed the primary and secondary screening based on the title abstract and full text. After data extraction, meta-analysis was performed using STATA software.
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
J Med Econ
January 2025
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
AimsThe cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D).
View Article and Find Full Text PDFSudden cardiac death after acute myocarditis with arrhythmic presentation: hunting for risk predictors - a systematic review and meta-analysis.
Open Heart
November 2024
Cardiothoracic Department, Santa Maria della Misericordia University Hospital, Udine, Italy
Background: Ventricular arrhythmias (VAs) frequently occur in the acute phase of myocarditis. Possible arrhythmic recurrences and the risk of sudden cardiac death (SCD) in this setting are reasons for concern, and limited data have been published to guide clinical management of these patients. The aim of the present paper is to report the incidence of major arrhythmic events, defined as sustained VA, SCD and appropriate implantable cardiac-defibrillator (ICD) treatment, in patients with acute myocarditis and ventricular arrhythmic phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!